1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,800 | 11,900 | 16:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GH RESEARCH Aktie jetzt für 0€ handeln | |||||
| 24.11. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.10. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.10. | Depression-Focused GH Research Shares Could See Significant Upside: Analyst | 4 | Benzinga.com | ||
| 09.10. | GH Research PLC - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.09. | Cantor Fitzgerald reiterates Overweight rating on GH Research stock | 2 | Investing.com | ||
| 09.09. | GH Research PLC - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.08. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.08. | GH Research GAAP EPS of -$0.15 | 1 | Seeking Alpha | ||
| 01.08. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | JMP reiterates Market Outperform rating on GH Research stock at $39 target | 6 | Investing.com | ||
| 23.07. | GH Research reports progress on FDA engagement for GH001 IND | 1 | Investing.com | ||
| 23.07. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | GH Research PLC: GH Research Announces Global Pivotal Program Plans and Further Development Updates | 433 | GlobeNewswire (Europe) | Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment... ► Artikel lesen | |
| 10.07. | GH Research stock awaits FDA response on clinical hold, says Canaccord | 1 | Investing.com | ||
| 09.07. | GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule | 3 | Insider Monkey | ||
| 20.06. | GH Research PLC: GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule | 318 | GlobeNewswire (Europe) | DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 15.05. | GH Research PLC: GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting | 98 | GlobeNewswire (Europe) | DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 08.05. | GH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates | 502 | GlobeNewswire (Europe) | Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents... ► Artikel lesen | |
| 27.02. | GH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business Updates | 410 | GlobeNewswire (Europe) | Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,160 | +0,31 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| VALNEVA | 3,642 | +3,70 % | Morgen-Update: Valneva-Aktie zieht durch - kommt jetzt die große Rallye? | ||
| BIOGEN | 148,90 | -0,20 % | Biogen stock rated Outperform by RBC Capital with $210 price target | ||
| BIOFRONTERA | 2,530 | +2,85 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| ILLUMINA | 114,98 | -0,09 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| NANOREPRO | 1,465 | -4,56 % | NanoRepro: Zwei Aufsichtsräte treten zurück | Nachdem NanoRepro am Freitag das Verlangen der HWT invest Aktiengesellschaft auf Einberufung einer außerordentlichen Hauptversammlung publik gemacht hat, sind nun zwei Aufsichtsräte zurückgetreten.... ► Artikel lesen | |
| OCUGEN | 1,202 | +0,84 % | Ocugen, Inc. - 8-K, Current Report | ||
| VAXART | 0,262 | -6,23 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| CYTODYN | 0,256 | +3,23 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| IMMUNIC | 0,517 | +4,76 % | EQS-News: Immunic AG: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
26.11.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| CEL-SCI | 3,960 | -11,21 % | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 | Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 14,370 | -0,96 % | Adaptive Biotechnologies inks two agreements with Pfizer in immunology | ||
| MUSTGROW BIOLOGICS | 0,448 | -3,24 % | Mustgrow Biologics Corp: Mustgrow CEO talks TerraSante demand, 2026 plans | ||
| GENPREX | 2,130 | +0,47 % | Genprex, Inc.: Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer | Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso®
AUSTIN, Texas, Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex"... ► Artikel lesen | |
| AMICUS THERAPEUTICS | 12,100 | -0,82 % | XFRA AM6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMICUS THERAPEUTICS... ► Artikel lesen |
Das Unternehmen GH RESEARCH PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,200 (+1,90 %) liegt der Kurs bei 10,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GH RESEARCH PLC finden Sie auf Wallstreet Online.